FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2555143315> ?p ?o ?g. }

• W2555143315 endingPage "582" @default.
• W2555143315 startingPage "574" @default.
• W2555143315 abstract "// Jing Wang 1, * , Xiaofeng Xue 2, * , Han Hong 3, * , Mingde Qin 4, * , Jin Zhou 2 , Qing Sun 4 , Hansi Liang 4 , Ling Gao 2 1 Department of General Surgery, The Second Hospital Affiliated to Jiaxing University, Jiaxing, 314000, Zhejiang Province, P.R. China 2 Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, 215006, Jiangsu Province, P.R. China 3 Department of Hepato-Pancreato-Biliary Surgery, Suzhou Municipal Hospital, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, 215006, Jiangsu Province, P.R. China 4 The Stem Cell and Biomedical Material Key Laboratory of Jiangsu Province (The State Key Laboratory Incubation Base), Soochow University, Suzhou, 215006, Jiangsu Province, P.R. China * These authors contributed equally to this work Correspondence to: Ling Gao, email: drxmliu@163.com Keywords: gastric cancer, microRNA, MiR-524-5p, SOX9, chemoresistance Received: July 14, 2016      Accepted: November 14, 2016      Published: November 21, 2016 ABSTRACT Cisplatin-based chemotherapy is the most commonly used treatment regimen for gastric cancer (GC), however, the resistance to cisplatin represents the key limitation for the therapeutic efficacy. Aberrant expression of MiR-524-5p appears to be involves in tumorigenesis and chemoresistance. However, the mechanism by which miR-524-5p mediates effects of cisplatin treatment in GC remains poorly understood. Expressions of MiR-524-5p was detected in GC tissues and cell lines by qRT-PCR. Cell proliferation was observed by MTT assay; Cell migration was detected by transwell migration and invasion assay. The targeting protein of miR-524-5p was identified by luciferase reporter assay and western blot. We found that downregulation of miR-524-5p in GC tissues and cell lines. SC-M1 and AZ521 cells resistant to cisplatin expressed low levels of miR-524-5p in comparison to the sensitive parental cells. Overexpression of miR-524-5p expression in SC-M1 and AZ521 cells inhibited cell proliferation, migration, and invasion, and conferred sensitivity to cisplatin-resistant GC cells. Subsequently, we identified SOX9 as a functional target protein of miR-524-5p and found that SOX9 overexpression could counteracts the chemosensitizing effects of miR-524-5p. These results provide novel insight into the regulation of GC tumorigenesis and progression by miRNAs. Restoration of miR-524-5p may have therapeutic potential against GC." @default.
• W2555143315 created "2016-11-30" @default.
• W2555143315 creator A5013211825 @default.
• W2555143315 creator A5013492995 @default.
• W2555143315 creator A5018070651 @default.
• W2555143315 creator A5022237643 @default.
• W2555143315 creator A5031451463 @default.
• W2555143315 creator A5045754976 @default.
• W2555143315 creator A5050762332 @default.
• W2555143315 creator A5071036191 @default.
• W2555143315 date "2016-11-21" @default.
• W2555143315 modified "2023-09-27" @default.
• W2555143315 title "Upregulation of microRNA-524-5p enhances the cisplatin sensitivity of gastric cancer cells by modulating proliferation and metastasis via targeting SOX9" @default.
• W2555143315 cites W144423133 @default.
• W2555143315 cites W1904052035 @default.
• W2555143315 cites W1993913862 @default.
• W2555143315 cites W2014946489 @default.
• W2555143315 cites W2042619042 @default.
• W2555143315 cites W2060567240 @default.
• W2555143315 cites W2085778840 @default.
• W2555143315 cites W2115072149 @default.
• W2555143315 cites W2117937119 @default.
• W2555143315 cites W2124756133 @default.
• W2555143315 cites W2128975886 @default.
• W2555143315 cites W2164277862 @default.
• W2555143315 cites W2170552969 @default.
• W2555143315 cites W2181371071 @default.
• W2555143315 cites W2192613912 @default.
• W2555143315 cites W2342769461 @default.
• W2555143315 cites W2510250688 @default.
• W2555143315 cites W2538155026 @default.
• W2555143315 cites W2545742373 @default.
• W2555143315 cites W2567715712 @default.
• W2555143315 doi "https://doi.org/10.18632/oncotarget.13479" @default.
• W2555143315 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5352179" @default.
• W2555143315 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27880941" @default.
• W2555143315 hasPublicationYear "2016" @default.
• W2555143315 type Work @default.
• W2555143315 sameAs 2555143315 @default.
• W2555143315 citedByCount "42" @default.
• W2555143315 countsByYear W25551433152017 @default.
• W2555143315 countsByYear W25551433152018 @default.
• W2555143315 countsByYear W25551433152019 @default.
• W2555143315 countsByYear W25551433152020 @default.
• W2555143315 countsByYear W25551433152021 @default.
• W2555143315 countsByYear W25551433152022 @default.
• W2555143315 crossrefType "journal-article" @default.
• W2555143315 hasAuthorship W2555143315A5013211825 @default.
• W2555143315 hasAuthorship W2555143315A5013492995 @default.
• W2555143315 hasAuthorship W2555143315A5018070651 @default.
• W2555143315 hasAuthorship W2555143315A5022237643 @default.
• W2555143315 hasAuthorship W2555143315A5031451463 @default.
• W2555143315 hasAuthorship W2555143315A5045754976 @default.
• W2555143315 hasAuthorship W2555143315A5050762332 @default.
• W2555143315 hasAuthorship W2555143315A5071036191 @default.
• W2555143315 hasBestOaLocation W25551433151 @default.
• W2555143315 hasConcept C104317684 @default.
• W2555143315 hasConcept C121608353 @default.
• W2555143315 hasConcept C126322002 @default.
• W2555143315 hasConcept C127561419 @default.
• W2555143315 hasConcept C143998085 @default.
• W2555143315 hasConcept C145059251 @default.
• W2555143315 hasConcept C2776694085 @default.
• W2555143315 hasConcept C2778239845 @default.
• W2555143315 hasConcept C2779013556 @default.
• W2555143315 hasConcept C502942594 @default.
• W2555143315 hasConcept C55493867 @default.
• W2555143315 hasConcept C555283112 @default.
• W2555143315 hasConcept C556039675 @default.
• W2555143315 hasConcept C71924100 @default.
• W2555143315 hasConcept C86803240 @default.
• W2555143315 hasConceptScore W2555143315C104317684 @default.
• W2555143315 hasConceptScore W2555143315C121608353 @default.
• W2555143315 hasConceptScore W2555143315C126322002 @default.
• W2555143315 hasConceptScore W2555143315C127561419 @default.
• W2555143315 hasConceptScore W2555143315C143998085 @default.
• W2555143315 hasConceptScore W2555143315C145059251 @default.
• W2555143315 hasConceptScore W2555143315C2776694085 @default.
• W2555143315 hasConceptScore W2555143315C2778239845 @default.
• W2555143315 hasConceptScore W2555143315C2779013556 @default.
• W2555143315 hasConceptScore W2555143315C502942594 @default.
• W2555143315 hasConceptScore W2555143315C55493867 @default.
• W2555143315 hasConceptScore W2555143315C555283112 @default.
• W2555143315 hasConceptScore W2555143315C556039675 @default.
• W2555143315 hasConceptScore W2555143315C71924100 @default.
• W2555143315 hasConceptScore W2555143315C86803240 @default.
• W2555143315 hasIssue "1" @default.
• W2555143315 hasLocation W25551433151 @default.
• W2555143315 hasLocation W25551433152 @default.
• W2555143315 hasLocation W25551433153 @default.
• W2555143315 hasLocation W25551433154 @default.
• W2555143315 hasOpenAccess W2555143315 @default.
• W2555143315 hasPrimaryLocation W25551433151 @default.
• W2555143315 hasRelatedWork W1499339123 @default.
• W2555143315 hasRelatedWork W1963617703 @default.
• W2555143315 hasRelatedWork W2013008691 @default.
• W2555143315 hasRelatedWork W2033672302 @default.
• W2555143315 hasRelatedWork W2626794881 @default.

• next